Very few consulting firms can rival our understanding of pharmaceutical markets and the robust data available to explain them. This specialized environment is no place for novices. We have worked on high profile patent litigation, antitrust cases, contract claims and injunction proceedings involving virtually every class of prescription drugs as well as many OTC products. Our experts regularly testify on drug development costs, probability of approvals, industry consolidation, order of entry effects, return on marketing, product lifecycle, generic substitution, commercial success, and the effects of competition on price and volume. This testimony is supported by a thorough understanding of regulatory processes, including NDA, Hatch-Waxman and BPCIA approvals and grants of exclusivity. Our understanding of the highly complex pharma supply chain and reimbursement systems is key to each of our analyses.

Our Pharma staff have decades of specialized industry experience that allows us to access and interpret governmental, proprietary and commercially published data sources. Stitching these data together produces unique insights into the behavior of any particular drug or class of drugs. Our recent book on this subject, Empirical Challenges in Pharma Litigation, provides a road map to the available data and illustrates many frequently faced modeling challenges. It includes chapters devoted specifically to patent damages, secondary considerations, antitrust damages, class certification, and international differences in drug markets. In addition to our in-house economists, we have established a broad network of highly regarded academics to assure that the niche requirements of any particular case can be satisfied.